ABIONYX Pharma Announces Its Strategy in Ophthalmology and New Positive Preclinical Results for the Deployment of Two Innovative Technology Platforms: Apotherapy and Biovectorization

TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announced today announced its strategy in ophthalmology and new positive preclinical results in two innovative technological platforms: apotherapy and biovectorisation. Cyrille TUPIN, Chief Executive Officer of ABIONYX Pharma, said: "The acquisition of IRIS Pharma, on